156 related articles for article (PubMed ID: 36655129)
1. Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells.
Wang C; Wang H; Zheng C; Li B; Liu Z; Zhang L; Yuan L; Xu P
ACS Med Chem Lett; 2023 Jan; 14(1):92-102. PubMed ID: 36655129
[TBL] [Abstract][Full Text] [Related]
2. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
[TBL] [Abstract][Full Text] [Related]
3. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
4. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1).
Dwivedi Y; Rizavi HS; Zhang H; Roberts RC; Conley RR; Pandey GN
Int J Neuropsychopharmacol; 2009 Nov; 12(10):1337-54. PubMed ID: 19835659
[TBL] [Abstract][Full Text] [Related]
5. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
6. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.
Wang H; Daouti S; Li WH; Wen Y; Rizzo C; Higgins B; Packman K; Rosen N; Boylan JF; Heimbrook D; Niu H
Cancer Res; 2011 Aug; 71(16):5535-45. PubMed ID: 21705440
[TBL] [Abstract][Full Text] [Related]
7. MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression.
Huth HW; Albarnaz JD; Torres AA; Bonjardim CA; Ropert C
Cell Signal; 2016 Sep; 28(9):1283-1291. PubMed ID: 27181679
[TBL] [Abstract][Full Text] [Related]
8. The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway.
Bilal F; Arenas EJ; Pedersen K; Martínez-Sabadell A; Nabet B; Guruceaga E; Vicent S; Tabernero J; Macarulla T; Arribas J
Cancer Res; 2021 Jul; 81(14):3849-3861. PubMed ID: 33903121
[TBL] [Abstract][Full Text] [Related]
9. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
Catalanotti F; Reyes G; Jesenberger V; Galabova-Kovacs G; de Matos Simoes R; Carugo O; Baccarini M
Nat Struct Mol Biol; 2009 Mar; 16(3):294-303. PubMed ID: 19219045
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
11.
Beuret L; Fortier-Beaulieu SP; Rondeau V; Roy S; Houde N; Balabanian K; Espéli M; Charron J
Front Cell Dev Biol; 2021; 9():639022. PubMed ID: 34386488
[TBL] [Abstract][Full Text] [Related]
12. Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2.
Zhang H; Feng H; Luo L; Zhou Q; Luo Z; Peng Y
Virus Res; 2010 Jun; 150(1-2):22-7. PubMed ID: 20172001
[TBL] [Abstract][Full Text] [Related]
13. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
14. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
15. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.
Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483
[TBL] [Abstract][Full Text] [Related]
16. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
17. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
18. The clinical development of MEK inhibitors.
Zhao Y; Adjei AA
Nat Rev Clin Oncol; 2014 Jul; 11(7):385-400. PubMed ID: 24840079
[TBL] [Abstract][Full Text] [Related]
19. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors.
Han S; Zhou V; Pan S; Liu Y; Hornsby M; McMullan D; Klock HE; Haugen J; Lesley SA; Gray N; Caldwell J; Gu XJ
Bioorg Med Chem Lett; 2005 Dec; 15(24):5467-73. PubMed ID: 16199156
[TBL] [Abstract][Full Text] [Related]
20. Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells.
Wu X; Noh SJ; Zhou G; Dixon JE; Guan KL
J Biol Chem; 1996 Feb; 271(6):3265-71. PubMed ID: 8621729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]